BrDMrisc – Online Brazilian Risk Score for Incident Type 2 Diabetes – ELSA-Brasil Cohort
DOI:
https://doi.org/10.11606/s15188787.2025059007088Keywords:
Diabetes Mellitus, Type II, Diagnostic Screening Program, Brazil, IncidencesAbstract
OBJECTIVE: To describe the Brazilian Diabetes Risk Score (BrDMrisc), an online calculator for estimating the risk of developing diabetes in 10 years, comparing it to other commonly used screening approaches to identify high-risk of future diabetes. METHODS: BrDMrisc is derived from 7.4-year follow-up data from ELSA-Brasil, a contemporary Brazilian cohort. Risk functions to predict future diabetes were based on socioeconomic, lifestyle, clinical, and laboratory variables, many of which are incorporated as continuous variables on a training sample including half of the analyzed cohort. We used ELSA-Brasil participant baseline data and incident diabetes cases detected during follow-up on the other half to compare the predictive capacity of BrDMrisc against traditional pre-diabetes screening strategies. RESULTS: BrDMrisc’s 27 risk functions offer versatility to the online app, enabling estimates based on differing combinations of clinical and laboratory findings, which present more favorable diagnostic properties than other recommended approaches. For example, the BrDMrisc function based on clinical data plus fasting glucose, when compared with detection using solely the presence of impaired fasting glucose (≥ 100 mg/dL), identified a more manageable fraction (20.0% versus 40.6%) of the population as high risk, with those identified as presenting a two-fold risk of developing diabetes (28.5% versus 17.1%). CONCLUSIONS: BrDMrisc diabetes risk calculator, based on data from a contemporary Brazilian cohort, is readily available online, versatile, and presents generally more favorable diagnostic properties than other commonly used screening strategies.
References
1. International Diabetes Federation. IDF Diabetes Atlas [Internet]. 2021 [cited 2025 Oct 8]. Available from: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_ Edition_2021.pdf
2. Institute for Health Metrics and Evaluation. GBD Foresight Visualization [Internet]. Seattle, WA: IHME; 2024 [cited 2025 Oct 8]. Available from: https://vizhub.healthdata.org/ gbd-foresight
3. American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl1):S34–9.
4. Kahn SE, Deanfield JE, Jeppesen OK, Emerson SS, Boesgaard TW, Colhoun HM, et al. Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT Trial. Diabetes Care. 2024 Aug 1;47(8):1350–9.
5. Barry E, Roberts S, Oke J, Vijayaraghavan S, Normansell R, Greenhalgh T. Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ. 2017 Jan 4;356:i6538.
6. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-Effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010 Aug;33(8):1872–94.
7. Ali MK, McKeever Bullard K, Imperatore G, Benoit SR, Rolka DB, Albright AL, et al. Reach and Use of diabetes prevention services in the United States, 2016-2017. JAMA Netw Open. 2019 May 10;2(5):e193160.
8. Penn L, Rodrigues A, Haste A, Marques MM, Budig K, Sainsbury K, et al. NHS diabetes prevention programme in England: formative evaluation of the programme in early phase implementation. BMJ Open. 2018 Feb;8(2):e019467.
9. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011 Nov;343:d7163.
10. American Diabetes Association Professional Practice Committee, ElSayed NA, McCoy RG, Aleppo G, Balapattabi K, Beverly EA, et al. 2. Diagnosis and classification of diabetes: standards of care in diabetes—2025. Diabetes Care. 2025 Jan;48(Suppl1):S27–49.
11. Lindström J, Tuomilehto J. The diabetes risk score. Diabetes Care. 2003 Mar;26(3):725–31.
12. Abbasi A, Peelen LM, Corpeleijn E, van der Schouw YT, Stolk RP, Spijkerman AMW, et al. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. BMJ. 2012 Sep;345:e5900.
13. Carrillo‐Larco RM, Aparcana‐Granda DJ, Mejia JR, Barengo NC, Bernabe‐Ortiz A. Risk scores for type 2 diabetes mellitus in Latin America: a systematic review of population‐based studies. Diabet Med. 2019 Dec;36(12):1573–84.
14. Pires de Sousa AG, Pereira AC, Marquezine GF, Marques do Nascimento-Neto R, Freitas SN C. Nicolato RL, et al. Derivation and external validation of a simple prediction model for the diagnosis of type 2 Diabetes Mellitus in the Brazilian urban population. Eur J Epidemiol. 2009 Feb;24(2):101–9.
15. Schmidt MI, Duncan BB, Mill JG, Lotufo PA, Chor D, Barreto SM, et al. Cohort profile: longitudinal study of adult health (ELSA-Brasil). Int J Epidemiol. 2015 Feb;44(1):68–75. 16. Bracco PA, Schmidt MI, Vigo A, Mill JG, Vidigal PG, Barreto SM, et al. Optimizing strategies to identify high risk of developing type 2 diabetes. Front Endocrinol. 2023 Jun;14:1166147.
17. Aquino EML, Barreto SM, Bensenor IM, Carvalho MS, Chor D, Duncan BB, et al. Brazilian longitudinal study of adult health (ELSA-Brasil): objectives and design. Am J Epidemiol. 2012 Feb;175(4):315–24.
18. Miller DK, Homan SM. Determining Transition probabilities: confusion and suggestions. Med Decis Making. 1994 Feb;14(1):52–8.
19. American Diabetes Association Professional Practice Committee, ElSayed NA, McCoy RG, Aleppo G, Balapattabi K, Beverly EA, et al. 2. Diagnosis and classification of diabetes: standards of care in diabetes—2025. Diabetes Care. 2025 Jan;48(Suppl1):S27–49.
20. Rodacki M, Cobas RA, Zajdenverg L, Silva Júnior WSD, Giacaglia L, Calliari LE, et al. Diagnóstico de diabetes mellitus [Internet]. 2024 [cited 2025 Feb 10]. Available from: https://diretriz.diabetes.org.br/diagnostico-de-diabetes-mellitus/
21. Saaristo T, Peltonen M, Keinänen-Kiukaanniemi S, Vanhala M, Saltevo J, Niskanen L, et al. National type 2 diabetes prevention programme in Finland: FIN-D2D. Int J Circumpolar Health. 2007 Apr;66(2):101–12.
22. Barim EM, McLellan KCP, Ribeiro RS, Carvalho JAMD, Lindström J, Tuomilehto J, et al. Translation and cultural adaptation into Brazilian Portuguese of the Finnish Diabetes Risk Score (FINDRISC) and reliability assessment. Rev Bras Epidemiol. 2020 Jun;23:e200060.
23. Carrillo-Larco RM, Aparcana-Granda DJ, Mejia JR, Bernabé-Ortiz A. FINDRISC in Latin America: a systematic review of diagnosis and prognosis models. BMJ Open Diabetes Res Care. 2020 Apr;8(1):e001169.
24. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May;344(18):1343–50.
25. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb;346(6):393–403.
Published
Issue
Section
License
Copyright (c) 2025 Revista de Saúde Pública

This work is licensed under a Creative Commons Attribution 4.0 International License.
Funding data
-
Ministério da Saúde
-
Ministério da Ciência, Tecnologia e Inovação
-
Financiadora de Estudos e Projetos
Grant numbers 01 06 0010.00;01 06 0212.00;01 06 0300.00;01 06 0278.00;01 06 0115.00;01 06 0071.00 -
Conselho Nacional de Desenvolvimento Científico e Tecnológico